Is Pasatru's Rare Disease Approval With Home Infusion Potential Altering The Investment ...

Regeneron Pharmaceuticals has received FDA approval for Pasatru, a monoclonal antibody therapy for fibrodysplasia ossificans progressiva (FOP) that allows monthly infusions potentially at home, enhancing its rare disease portfolio. While Pasatru strengthens Regeneron's innovation narrative, its impact on near-term revenue is limited compared to the ophthalmology franchise facing pricing and competition pressures.

This Wire brief sits within Fusion42's coverage of Biotech.